Cellular Senescence as a Mechanism and Target in Chronic Lung Diseases

Клеточное старение как механизм и мишень при хронических заболеваниях легких
Peter John Barnes, Louise Donnelly, Jonathan R. Baker
2019-03-12

cellular senescencechronic obstructive pulmonary diseaseidiopathic pulmonary fibrosissenescence-associated secretory phenotypesenolytic therapies
Abstract Cellular senescence is now considered an important driving mechanism for chronic lung diseases, particularly chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis. Cellular senescence is due to replicative and stress-related senescence with activation of p53 and p16INK4a, respectively, leading to activation of p21CIP1 and cell cycle arrest. Senescent cells secrete multiple inflammatory proteins known as the senescence-associated secretory phenotype, leading to low-grade chronic inflammation, which further drives senescence. Loss of key antiaging molecules sirtuin-1 and sirtuin-6 may be important in acceleration of aging and arises from oxidative stress reducing phosphatase PTEN (phosphatase tensin homolog), thereby activating PI3K (phosphoinositide-3-kinase) and mTOR (mammalian target of rapamycin). MicroRNA-34a (miR-34a), which is regulated by PI3K–mTOR signaling, plays a pivotal role in reducing sirtuin-1/6, and its inhibition with an antagomir results in their restoration, reducing markers of senescence, reducing senescence-associated secretory phenotype, and reversing cell cycle arrest in epithelial cells from peripheral airways of patients with COPD. miR-570 is also involved in reduction of sirtuin-1 and cellular senescence and is activated by p38 mitogen-activated protein kinase. These miRNAs may be released from cells in extracellular vesicles that are taken up by other cells, thereby spreading senescence locally within the lung but also outside the lung through the circulation; this may account for comorbidities of COPD and other lung diseases. Understanding the mechanisms of cellular senescence may result in new treatments for chronic lung disease, either by inhibiting PI3K–mTOR signaling, by inhibiting specific miRNAs, or by deletion of senescent cells with senolytic therapies, already shown to be effective in experimental lung fibrosis.
1
Cellular senescence is identified as a major pathogenic mechanism in chronic lung diseases, especially COPD and idiopathic pulmonary fibrosis.
2
In COPD airway epithelial cells, inhibiting miR-34a with an antagomir restores sirtuin-1/6, reduces senescence markers and inflammatory secretion, and reverses cell-cycle arrest.
3
Oxidative-stress-driven loss of PTEN may activate PI3K–mTOR signaling, reducing the antiaging molecules sirtuin-1 and sirtuin-6 and accelerating cellular aging.
4
Replicative and stress-induced senescence activate p53/p21CIP1 and p16INK4a pathways, causing cell-cycle arrest and a pro-inflammatory senescence-associated secretory phenotype.
5
Senescence-associated microRNAs may spread through extracellular vesicles, potentially propagating lung senescence and contributing to systemic comorbidities; therapeutic strategies include PI3K–mTOR inhibition, miRNA targeting, and senolytic removal of senescent cells.

Cellular senescence in chronic lung diseases, particularly COPD and idiopathic pulmonary fibrosis

The molecular mechanisms, inflammatory signaling, intercellular spread, and therapeutic targeting of cellular senescence

Publication Details
Publication Date
2019-03-12
Journal
Publisher
ISSN
Cited by
612
Access Type
Author Information
Authors
Peter John Barnes
Louise Donnelly
Jonathan R. Baker
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%